

# Association between DNA methylation of the CUB and sushi multiple domains 1 gene and schizophrenia

Mohd Asyraf Abdull Jalil<sup>a</sup>, Nour El Huda Abd Rahim<sup>a</sup>, Hanisah Mohd Noor<sup>b</sup>, Noorul Amilin Harun<sup>c</sup>, Norlelawati A. Talib<sup>d</sup>

<sup>a</sup>*Department of Basic Medical Sciences, Kulliyah of Medicine, International Islamic University Malaysia, 25200 Kuantan, Pahang.*

<sup>b</sup>*Department of Psychiatry, Faculty of Medicine, Universiti Sultan Zainal Abidin, 23200 Kuala Terengganu, Terengganu.*

<sup>c</sup>*Department of Psychiatry and Mental Health, Hospital Tengku Ampuan Afzan, 25100 Kuantan, Pahang.*

<sup>d</sup>*Department of Pathology and Laboratory Medicine, Sultan Ahmad Shah Medical Centre, International Islamic University Malaysia, 25200 Kuantan, Pahang.*



## Age of Onset

- Early adulthood
- Productive years

## Employment

- 80% remain unemployed (*Dahlan et al, 2014*)
- Dependent on family

## Economic loss

- RM 428 million = 0.04% GDP cost to Nation (*Teoh et al, 2017*)

# Signs & Symptoms of Schizophrenia

## Positive Symptoms



Dopamine  
excess in  
mesolimbic  
system

**Disorganized  
speech and thoughts**

## Negative Symptoms



Dopamine  
deficit in  
mesocortical  
system?

**Blunted affect**


## Cognitive Symptoms



Glutamatergic  
synaptic  
dysregulation  
?

**Impaired sensory  
perception**


# Neurodevelopment



# ***SYNAPSE PRUNING***

- ❑ Developmental process of targeted synapse elimination
- ❑ Performed by microglia
- ❑ Complement system seems to be important mediators (*Stevens et al., 2007; Sekar et al., 2016; Comer et al., 2020*)
- ❑ Schizophrenia brains have fewer synapse from increased elimination by microglia (*Sellgren et al., 2019*)

# Neurodevelopment



# CSMD1

- ❑ A large gene, about 2 Mb on Chr 8p23.2
- ❑ Potentially a tumour suppressor gene  
*(Gialeli et al., 2021)*
- ❑ Code for multiple CUB domains and complement control protein domains (sushi)
- ❑ Expressed mainly in the brain and testis  
*(Escudero-Esparza et al., 2013)*
- ❑ Inhibits deposition of C3b, co-factor for C3b degradation and membrane attack complex (MAC) assembly *(Escudero-Esparza et al., 2013)*

# CSMD1 & Schizophrenia

GWAS: association of SNPs with schizophrenia (*Schizophrenia Working Group of the Psychiatric Genomics, 2014*)

SNPs associated with cognitive dysfunction (*Koiliari et al. 2014; Athanasiu et al., 2017; Stepanov et al., 2017;*)

Low level of expression in schizophrenia (*Liu et al., 2019; El Gayed et al., 2021*)

Deletion leads to altered behaviour similar to schizophrenia symptoms in mouse model (*Steen et al 2013*)

Opposes complement action on neural tissues (*Baum et al., 2020*)



# DNA METHYLATION






Image credit: BOGOBiology

# ***DNA METHYLATION of CSMD1 in Schizophrenia***



# METHODOLOGY





Assembly exceptions  
chromosome 8



Assembly exceptions

## CSMD1



# PANSS & PSP

<b>Positive and Negative Syndrome Scale (PANSS)</b>	<b>Personal and Social Performance Scale</b>
Clinician administered	Clinician administered
30 items, 3 to 5 domains	4 domains
7 point Likert Scale	6 point Likert Scale
1 (absent) – 7 (extreme)	Absent to Very Severe
Score 30 (absent of symptom) – 210 (most severe symptom)	Score 0 (worst function) – 100 (best function)


# RESULTS - SOCIODEMOGRAPHICS

**Table 1** Sociodemographic characteristics of study participants.

Sociodemographic Characteristics	Schizophrenia patients, n = 183	Healthy controls, n = 212	p-value
Age, Years			
median	39.0	38.0	0.309 <sup>1</sup>
(IQR)	(31.0 - 48.0)	(31.0 – 45.0)	
Gender			
Male, % (n)	61.7 (113)	61.3 (130)	0.931 <sup>2</sup>
Female, % (n)	38.3 (70)	38.7 (82)	
Ethnicity			
Malay, % (n)	79.2 (145)	72.6 (154)	0.128 <sup>2</sup>
Chinese, % (n)	20.8 (38)	27.4 (58)	

<sup>1</sup>Mann-Whitney U test; <sup>2</sup>Chi-square test; \*statistically significant. n = number; IQR = interquartile range; BMI = Body Mass Index. p-value <0.05 is considered significant at 95% confidence interval.

# RESULTS - CSMD1 DNA METHYLATION in SZ vs HC



Median PMR Schizophrenia ( $n = 183$ ): 1.45%

Median PMR Healthy Controls ( $n = 212$ ): 2.48%

$U = 15484.5, p = 0.001$


# DISCUSSION

- ❑ Differential methylation of *CSMD1* gene or promoter has not been reported previously. The closest differentially methylated position reported by an EWAS is 700,000 bp downstream (*Hannon et al., 2021*)
- ❑ Higher methylation levels of *CSMD1* has been reported in several types of malignancy (*Kamal et al., 2017; Shull et al., 2013*) causing silencing of the gene.
- ❑ DNA methylation of a may also cause increased expression (*Rauluseviciute et al., 2020; Yang et al., 2014*), and therefore is locus and context dependent (*Dhar et al., 2021*)




# RESULTS - PSYCHOPATHOLOGY

Total PANSS




PSP




# RESULTS - PSYCHOPATHOLOGY


Positive domain




Negative domain




Disorganization domain



Excitement domain





Depressive domain



# DISCUSSION

- ❑ Schizophrenia is a heterogenous and complex diagnosis. Multiple pathophysiology may be involved.
- ❑ Using PANSS can help identify the affected phenotypes. In this study, only positive symptoms were linked with *CSMD1* methylation.
- ❑ El Gayed et al. (2021) found lower expression of *CSMD1* associated with risk of psychosis
- ❑ Other studies had found association between certain variants (SNP) of *CSMD1* and cognitive dysfunction (Koiliari et al., 2014; Athanasiu et al., 2017; Stepanov et al. 2017)
- ❑ Mice with *CSMD1* deletion shows altered behaviour akin to negative symptoms (Steen et al., 2013)

# RESULTS - SOCIODEMOGRAPHICS vs CSMD1 DNA METHYLATION



Median PMR Malays ( $n = 299$ ): 2.24%  
Median PMR Chinese ( $n = 96$ ): 0.63%  
 $U = 8923, p < 0.001$

# DISCUSSION

- ❑ Age has been found to be correlated with methylation of many genes (*Jung & Pfeifer, 2015*)
- ❑ Differences in DNA methylation between different ethnicities could be explained by difference in ancestry or environmental exposures (*Galanter et al., 2017*)
- ❑ Since methylation is reversible, further exploration on the mechanism underlying this association could eventually be useful for novel treatment strategy in the future.

# ***LIMITATIONS***

- ❑ Results using peripheral blood may not reflect methylation in brain tissue
- ❑ We did not manage to test the association between DNA methylation and the expression of *CSMD1*.
- ❑ The DNA methylation of other CpG island inside *CSMD1* or other genes related to synapse pruning/ plasticity were not studied together.
- ❑ Recruited patients were mostly stable on medication, therefore the methylation levels during active/ relapse phase could not be evaluated.



## CONCLUSION

- ❑ Lower DNA methylation of *CSMD1* may be involved in the pathogenesis of schizophrenia, particularly the positive symptoms.
- ❑ The cause-effect relationship and the exact mechanism need to be investigated in future studies.

# REFERENCES

- Abd El Gayed, E. M., Rizk, M. S., Ramadan, A. N., & Bayomy, N. R. (2021). mRNA Expression of the CUB and Sushi Multiple Domains 1 (CSMD1) and Its Serum Protein Level as Predictors for Psychosis in the Familial High-Risk Children and Young Adults. *ACS Omega*, 6(37), 24128-24138. doi:10.1021/acsomega.1c03637
- Baum, M. L., Wilton, D. K., Muthukumar, A., Fox, R. G., Carey, A., Crotty, W., . . . Stevens, B. (2020). CUB and Sushi Multiple Domains 1 (CSMD1) opposes the complement cascade in neural tissues. *bioRxiv*, 2020.2009.2011.291427. doi:10.1101/2020.09.11.291427
- [BOGObiology]. (2017, October 11). Epigenetics: Nature vs. Nurture. [Video File]. Retrieved from <https://youtu.be/Q8BMP6HDlco>
- Comer, A. L., Jinadasa, T., Sriram, B., Phadke, R. A., Kretsge, L. N., Nguyen, T. P. H., . . . Cruz-Martin, A. (2020). Increased expression of schizophrenia-associated gene C4 leads to hypoconnectivity of prefrontal cortex and reduced social interaction. *PLoS Biol*, 18(1), e3000604. doi:10.1371/journal.pbio.3000604
- Dahlan, R., Midin, M., Shah, S. A., Nik Jaafar, N. R., Abdul Rahman, F. N., Baharudin, A., . . . Sidi, H. (2014). Functional remission and employment among patients with schizophrenia in Malaysia. *Compr Psychiatry*, 55 Suppl 1, S46-51. doi:10.1016/j.comppsy.2013.03.007
- Dhar, G. A., Saha, S., Mitra, P., & Nag Chaudhuri, R. (2021). DNA methylation and regulation of gene expression: Guardian of our health. *Nucleus (Calcutta)*, 64(3), 259-270. doi:10.1007/s13237-021-00367-y
- Escudero-Esparza, A., Kalchishkova, N., Kurbasic, E., Jiang, W. G., & Blom, A. M. (2013). The novel complement inhibitor human CUB and Sushi multiple domains 1 (CSMD1) protein promotes factor I-mediated degradation of C4b and C3b and inhibits the membrane attack complex assembly. *FASEB J*, 27(12), 5083-5093. doi:10.1096/fj.13-230706
- Galanter, J. M., Gignoux, C. R., Oh, S. S., Torgerson, D., Pino-Yanes, M., Thakur, N., . . . Zaitlen, N. (2017). Differential methylation between ethnic sub-groups reflects the effect of genetic ancestry and environmental exposures. *Elife*, 6. doi:10.7554/eLife.20532



# REFERENCES

- Gialeli, C., Tuysuz, E. C., Staaf, J., Guleed, S., Paciorek, V., Morgelin, M., . . . Blom, A. M. (2021). Complement inhibitor CSMD1 modulates epidermal growth factor receptor oncogenic signaling and sensitizes breast cancer cells to chemotherapy. *J Exp Clin Cancer Res*, *40*(1), 258. doi:10.1186/s13046-021-02042-1
- Hannon, E., Dempster, E. L., Mansell, G., Burrage, J., Bass, N., Bohlken, M. M., . . . Mill, J. (2021). DNA methylation meta-analysis reveals cellular alterations in psychosis and markers of treatment-resistant schizophrenia. *Elife*, *10*. doi:10.7554/eLife.58430
- Jung, M., & Pfeifer, G. P. (2015). Aging and DNA methylation. *BMC Biol*, *13*, 7. doi:10.1186/s12915-015-0118-4
- Kamal, M., Holliday, D. L., Morrison, E. E., Speirs, V., Toomes, C., & Bell, S. M. (2017). Loss of CSMD1 expression disrupts mammary duct formation while enhancing proliferation, migration and invasion. *Oncol Rep*, *38*(1), 283-292. doi:10.3892/or.2017.5656
- Koiliari, E., Roussos, P., Pasparakis, E., Lencz, T., Malhotra, A., Siever, L. J., . . . Bitsios, P. (2014). The CSMD1 genome-wide associated schizophrenia risk variant rs10503253 affects general cognitive ability and executive function in healthy males. *Schizophr Res*, *154*(1-3), 42-47. doi:10.1016/j.schres.2014.02.017
- Liu, Y., Fu, X., Tang, Z., Li, C., Xu, Y., Zhang, F., . . . Zhu, C. (2019). Altered expression of the CSMD1 gene in the peripheral blood of schizophrenia patients. *BMC Psychiatry*, *19*(1), 113. doi:10.1186/s12888-019-2089-4
- Rauluseviciute, I., Drablos, F., & Rye, M. B. (2020). DNA hypermethylation associated with upregulated gene expression in prostate cancer demonstrates the diversity of epigenetic regulation. *BMC Med Genomics*, *13*(1), 6. doi:10.1186/s12920-020-0657-
- Schizophrenia Working Group of the Psychiatric Genomics, C. (2014). Biological insights from 108 schizophrenia-associated genetic loci. *Nature*, *511*(7510), 421-427. doi:10.1038/nature13595

# REFERENCES

- Sekar, A., Bialas, A. R., de Rivera, H., Davis, A., Hammond, T. R., Kamitaki, N., . . . McCarroll, S. A. (2016). Schizophrenia risk from complex variation of complement component 4. *Nature*, *530*(7589), 177-183. doi:10.1038/nature16549
- Sellgren, C. M., Gracias, J., Watmuff, B., Biag, J. D., Thanos, J. M., Whittredge, P. B., . . . Perlis, R. H. (2019). Increased synapse elimination by microglia in schizophrenia patient-derived models of synaptic pruning. *Nat Neurosci*, *22*(3), 374-385. doi:10.1038/s41593-018-0334-7
- Shull, A. Y., Clendenning, M. L., Ghoshal-Gupta, S., Farrell, C. L., Vangapandu, H. V., Dudas, L., . . . Buckhaults, P. J. (2013). Somatic mutations, allele loss, and DNA methylation of the Cub and Sushi Multiple Domains 1 (CSMD1) gene reveals association with early age of diagnosis in colorectal cancer patients. *PLoS One*, *8*(3), e58731. doi:10.1371/journal.pone.0058731
- Steen, V. M., Nepal, C., Erslund, K. M., Holdhus, R., Naevdal, M., Ratvik, S. M., . . . Havik, B. (2013). Neuropsychological deficits in mice depleted of the schizophrenia susceptibility gene CSMD1. *PLoS One*, *8*(11), e79501. doi:10.1371/journal.pone.0079501
- Stepanov, V., Marusin, A., Vagaitseva, K., Bocharova, A., & Makeeva, O. (2017). Genetic Variants in CSMD1 Gene Are Associated with Cognitive Performance in Normal Elderly Population. *Genet Res Int*, *2017*, 6293826. doi:10.1155/2017/6293826
- Stevens, B., Allen, N. J., Vazquez, L. E., Howell, G. R., Christopherson, K. S., Nouri, N., . . . Barres, B. A. (2007). The classical complement cascade mediates CNS synapse elimination. *Cell*, *131*(6), 1164-1178. doi:10.1016/j.cell.2007.10.036
- Teoh, S. L., Chong, H. Y., Abdul Aziz, S., Chemi, N., Othman, A. R., Md Zaki, N., . . . Chaiyakunapruk, N. (2017). The economic burden of schizophrenia in Malaysia. *Neuropsychiatr Dis Treat*, *13*, 1979-1987. doi:10.2147/NDT.S137140
- van der Gaag, M., Hoffman, T., Remijsen, M., Hijman, R., de Haan, L., van Meijel, B., . . . Wiersma, D. (2006). The five-factor model of the Positive and Negative Syndrome Scale II: a ten-fold cross-validation of a revised model. *Schizophr Res*, *85*(1-3), 280-287. doi:10.1016/j.schres.2006.03.021
- Yang, X., Han, H., De Carvalho, D. D., Lay, F. D., Jones, P. A., & Liang, G. (2014). Gene body methylation can alter gene expression and is a therapeutic target in cancer. *Cancer Cell*, *26*(4), 577-590. doi:10.1016/j.ccr.2014.07.028

# ***ACKNOWLEDGEMENT***

- This study was supported by The Ministry of Higher Education Malaysia via the Fundamental Research Grant Scheme (FRGS19-001-0609)
- Department of Psychiatry and Mental Health, Hospital Tengku Ampuan Afzan (HTAA), Kuantan
- Blood Bank, HTAA

***THANK YOU***